The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2018 Dec 19

PMID 30560130

Authors

Joanne K Gardner

Connie Jackaman

Cyril D S Mamotte

Delia J Nelson

Affiliations

Soon will be listed here.

Abstract

Aging is associated with an increased incidence of cancer. One contributing factor could be modulation of immune cells responsible for anti-tumor responses, such as dendritic cells (DCs) and T cells. These immunological changes may also impact the efficacy of cancer immunotherapies in the elderly. The effects of healthy aging on DCs and T cells, and their impact on anti-mesothelioma immune responses, had not been reported. This study examined DCs and T cells in young (2-5 months; equivalent to 16-26 human years) and elderly (20-24 months; equivalent to 60-70 human years) healthy and mesothelioma-bearing C57BL/6J mice. During healthy aging, elderly lymph nodes adopted a regulatory profile, characterized by: (i) increased plasmacytoid DCs, (ii) increased expression of the adenosine-producing enzyme CD73 on CD11c cells, and (iii) increased expression of multiple regulatory markers (including CD73, the adenosine A2B receptor, CTLA-4, PD-1, ICOS, LAG-3, and IL-10) on CD8 and CD4 T cells, compared to lymph nodes from young mice. Although mesotheliomas grew faster in elderly mice, the increased regulatory status observed in healthy elderly lymph node DCs and T cells was not further exacerbated. However, elderly tumor-bearing mice demonstrated reduced MHC-I, MHC-II and CD80 on CD11c cells, and decreased IFN-γ by CD8 and CD4 T cells within tumors, compared to young counterparts, implying loss of function. An agonist CD40 antibody based immunotherapy was less efficient at promoting tumor regression in elderly mice, which may be due to: (i) failure of elderly CD8 T cells to up-regulate perforin, and (ii) increased expression of multiple regulatory markers on CD11c cells and T cells in elderly tumor-draining lymph nodes (including CD73, PD-1, ICOS, LAG-3, and TGF-β). Our findings suggest that checkpoint blockade may improve responses to immunotherapy in elderly hosts with mesothelioma, and warrants further investigation.

References

Provinciali M, Argentati K, Tibaldi A . Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther. 2000; 7(7):624-32. DOI: 10.1038/sj.gt.3301131. View

Pooley J, Heath W, Shortman K . Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. 2001; 166(9):5327-30. DOI: 10.4049/jimmunol.166.9.5327. View

Akbari O, DeKruyff R, Umetsu D . Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001; 2(8):725-31. DOI: 10.1038/90667. View

Young M, Kolesiak K, Achille N, Meisinger J, Gonzalez E, Liu S . Impact of aging on immune modulation by tumor. Cancer Immunol Immunother. 2001; 50(6):315-20. PMC: 11036818. DOI: 10.1007/s002620100203. View

Carter L, Fouser L, Jussif J, Fitz L, Deng B, Wood C . PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002; 32(3):634-43. DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9. View

Win S, Uenaka A, Nakayama E . Immune responses against allogeneic and syngeneic tumors in aged C57BL/6 mice. Microbiol Immunol. 2002; 46(7):513-9. DOI: 10.1111/j.1348-0421.2002.tb02728.x. View

Warrington K, Vallejo A, Weyand C, Goronzy J . CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood. 2002; 101(9):3543-9. DOI: 10.1182/blood-2002-08-2574. View

Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A . Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine. 2003; 21(9-10):843-8. DOI: 10.1016/s0264-410x(02)00530-3. View

Murphy W, Welniak L, Back T, Hixon J, Subleski J, Seki N . Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol. 2003; 170(5):2727-33. DOI: 10.4049/jimmunol.170.5.2727. View

10.

Jackaman C, Bundell C, Kinnear B, Smith A, Filion P, van Hagen D . IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003; 171(10):5051-63. DOI: 10.4049/jimmunol.171.10.5051. View

11.

Zhang H, Conrad D, Butler J, Zhao C, Blay J, Hoskin D . Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases. J Immunol. 2004; 173(2):932-44. DOI: 10.4049/jimmunol.173.2.932. View

12.

Munn D, Sharma M, Hou D, Baban B, Lee J, Antonia S . Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004; 114(2):280-90. PMC: 449750. DOI: 10.1172/JCI21583. View

13.

Welniak L, Shorts L, Subleski J, Blazar B, Wiltrout R, Murphy W . Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant. 2004; 10(8):534-9. DOI: 10.1016/j.bbmt.2004.05.006. View

14.

Lustgarten J, Dominguez A, Thoman M . Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol. 2004; 173(7):4510-5. DOI: 10.4049/jimmunol.173.7.4510. View

15.

Stumbles P, Himbeck R, Frelinger J, Collins E, Lake R, Robinson B . Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol. 2004; 173(10):5923-8. DOI: 10.4049/jimmunol.173.10.5923. View

16.

Workman C, Vignali D . Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 2005; 174(2):688-95. DOI: 10.4049/jimmunol.174.2.688. View

17.

Munn D, Sharma M, Baban B, Harding H, Zhang Y, Ron D . GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22(5):633-42. DOI: 10.1016/j.immuni.2005.03.013. View

18.

Shi M, Bi X, Xu S, He Y, Guo X, Xiang J . Increased susceptibility of tumorigenicity and decreased anti-tumor effect of DC vaccination in aged mice are potentially associated with increased number of NK1.1+CD3+ NKT cells. Exp Oncol. 2005; 27(2):125-9. View

19.

Sharma S, Dominguez A, Lustgarten J . Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol. 2005; 41(1):78-84. DOI: 10.1016/j.exger.2005.10.002. View

20.

Munn D, Mellor A . The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006; 213:146-58. DOI: 10.1111/j.1600-065X.2006.00444.x. View